In conclusion, in the Dutch sub-cohort of the TEAM trial, our findings revealed that CAB provides a prognostic signature for the clinical outcome for postmenopausal women with early breast cancer, HR-positive, HER2-negative disease of ten-year follow-up. The gene discussed is ERBB2; the disease is breast cancer.